A new white paper from PYA helps blood centers assess the effects of large-scale consolidation, offering guidance these organizations can use for positioning themselves “to survive and thrive as the blood transfusion industry transforms.”
The demand for blood products in the U.S. blood transfusion industry has declined considerably over the last five years. This decreasing demand, along with lower blood prices, decreased availability, and higher costs associated with obtaining blood products, is driving industry consolidation, according to a newly released white paper from PYA.
The new paper, titled “Blood Centers Should Position Themselves to Be Agents (Not Victims) of Change,” draws upon several recent reviews, reports, and studies to further explain the factors driving consolidation. The white paper also cites examples of the industry’s response, describing a wave of mergers that observers expect will continue. However, the paper cautions that “bigger” may not necessarily mean “better” when it comes to efficiency, and urges organizations to conduct in-depth analyses when determining whether, how, and with whom to consolidate in order to find the “right size.”
The white paper also draws parallels between the blood transfusion industry and other segments of healthcare that have undergone similar change. It explores two forms of merger structures employed by the mental health industry at the crux of its consolidation challenges, and provides a vignette of consolidation among community mental health centers, from which blood centers might glean valuable lessons.
PYA assists healthcare organizations in meeting challenges by providing education for governing bodies, leadership teams, and medical staffs; facilitating dialogue in the board room; performing governance effectiveness reviews; and identifying, developing, and implementing strategic initiatives.